CSL Ltd
CSL: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|Ns | LOCK|$dK< | LOCK|%p&d!?z |
CSL Earnings: CEO Change Is Welcome but Relatively Soft Plasma Performance to Postpone Recovery
CSL's interim 2026 underlying EBIT fell 3% on 5% lower plasma sales. Full-year guidance of mid-single-digit earnings growth was reaffirmed, and the Seqirus and Vifor divisions fared relatively well. But the soft plasma result and retirement of CEO Paul McKenzie sent shares down 11%.
